[
  {
    "ts": "2025-10-15T21:45:04+00:00",
    "headline": "Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know",
    "summary": "Eli Lilly (LLY) concluded the recent trading session at $826.57, signifying a +1.75% move from its prior day's close.",
    "url": "https://finance.yahoo.com/news/eli-lilly-lly-outpaces-stock-214504357.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "2ca9ff32-5082-3744-ae44-8027b8861467",
      "content": {
        "id": "2ca9ff32-5082-3744-ae44-8027b8861467",
        "contentType": "STORY",
        "title": "Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know",
        "description": "",
        "summary": "Eli Lilly (LLY) concluded the recent trading session at $826.57, signifying a +1.75% move from its prior day's close.",
        "pubDate": "2025-10-15T21:45:04Z",
        "displayTime": "2025-10-15T21:45:04Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/023168c7ea091c342492be3899b280af",
          "originalWidth": 900,
          "originalHeight": 618,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AH29CN1G1bp_AgmMAtiHlQ--~B/aD02MTg7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/023168c7ea091c342492be3899b280af.cf.webp",
              "width": 900,
              "height": 618,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xcYKn6Tda5Sy52WTJQhMtA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/023168c7ea091c342492be3899b280af.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-lly-outpaces-stock-214504357.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-lly-outpaces-stock-214504357.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "^SPX"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "^IXIC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-15T11:15:40+00:00",
    "headline": "Eli Lilly Says Diabetes Drug Orforglipron Meets Key Goals in Two Phase 3 Trials",
    "summary": "Eli Lilly (LLY) said Wednesday its experimental drug, orforglipron, met primary and all key secondar",
    "url": "https://finance.yahoo.com/news/eli-lilly-says-diabetes-drug-111540284.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "d8668088-59e4-3ded-87a7-9f6cbf4c3d96",
      "content": {
        "id": "d8668088-59e4-3ded-87a7-9f6cbf4c3d96",
        "contentType": "STORY",
        "title": "Eli Lilly Says Diabetes Drug Orforglipron Meets Key Goals in Two Phase 3 Trials",
        "description": "",
        "summary": "Eli Lilly (LLY) said Wednesday its experimental drug, orforglipron, met primary and all key secondar",
        "pubDate": "2025-10-15T11:15:40Z",
        "displayTime": "2025-10-15T11:15:40Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-says-diabetes-drug-111540284.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-says-diabetes-drug-111540284.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-15T11:03:00+00:00",
    "headline": "Lilly, battling skepticism, reinforces GLP-1 pill’s case with new study data",
    "summary": "Some Wall Street analysts have questioned orforglipron’s sales outlook in obesity, but see great potential in diabetes, where on Wednesday it succeeded in two more late-stage trials.",
    "url": "https://www.biopharmadive.com/news/orforglipron-diabetes-achieve-sglt2-study-results/802820/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "f557613a-a632-3204-b888-bfa01e619c4d",
      "content": {
        "id": "f557613a-a632-3204-b888-bfa01e619c4d",
        "contentType": "STORY",
        "title": "Lilly, battling skepticism, reinforces GLP-1 pill’s case with new study data",
        "description": "",
        "summary": "Some Wall Street analysts have questioned orforglipron’s sales outlook in obesity, but see great potential in diabetes, where on Wednesday it succeeded in two more late-stage trials.",
        "pubDate": "2025-10-15T11:03:00Z",
        "displayTime": "2025-10-15T11:03:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/05d05df3413a7fde79bd31fd45897d59",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "A sign with the company logo sits outside of the headquarters campus of Eli Lilly and Company on March 17, 2024 in Indianapolis, Indiana.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Hiy1QKsIu_1p97mRQJIn_g--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/05d05df3413a7fde79bd31fd45897d59.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Rwp7_GnVU.OErtnHMlF_TQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/05d05df3413a7fde79bd31fd45897d59.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/orforglipron-diabetes-achieve-sglt2-study-results/802820/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lilly-battling-skepticism-reinforces-glp-110300541.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "AZN.L"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]